ILAE-Asia and Oceania
Epilepsy in Asia: Disease burden, management barriers, and challenges
Eugen Trinka, Patrick Kwan, ByungIn Lee and Amitabh Dash
Version of Record online: 28 JUN 2018 | DOI: 10.1111/epi.14458
Latest News
World News
Global, regional, and national burden of epilepsy, 1990-2016
Despite the decrease in the disease burden from 1990 to 2016, epilepsy is still an important cause of disability and mortality. Standardised collection of data on epilepsy in population representative surveys will strengthen the estimates, particularly in countries for which we currently have no or sparse data...
18 February, 2019
Clinical Research
Factors predicting cessation of status epilepticus in clinical practice – data from a prospective observational registry (SENSE)
In clinical practice, treatment guidelines were not followed in a substantial proportion of patients. This under‐dosing correlated with lack of cessation of SE. Our data suggest that sufficiently dosed benzodiazepines should be used as first treatment step.
4 February, 2019
World News
International Epilepsy Day is February 11
Mark your calendar! International Epilepsy Day is a special event which promotes awareness of epilepsy in more than 120 countries each year. Every year on the second Monday of February people join together to celebrate and highlight the problems faced by people with epilepsy, their families and…
14 January, 2019
About ILAE
Chapter spotlight: Epilepsy Society of Thailand (EST)
Since it was established in 1996, the mission of EST has been to improve the standard of care for epileptic patients, to improve the quality of treatment, and to provide up-to-date knowledge about epilepsy to both general practitioners and patients. In 2019 the EST celebrates its twenty-third…
9 January, 2019
Clinical Research
Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures
In previously seizure‐free patients, switching the manufacturer of antiepileptic medications was associated with a higher risk for seizure recurrence. Our retrospective approach does not allow us to determine whether other changes in medical care at the same time could contribute to the recurrence. However, it would be prudent to avoid switching the manufacturer of anticonvulsants in seizure‐free patients. Ann Neurol 2018;84:918–925
2 January, 2019
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community